Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.59 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341921 | 0.89 | F10 (0.63) | F10PLGPLATKLK1PRSS1 | |
| SCHEMBL890913 | 0.80 | F10 (0.59) | F10PLGPLATKLK1PRSS1 | |
| SCHEMBL890595 | 0.79 | F10 (0.61) | F10PLGPLATKLK1PRSS1 | |
| SCHEMBL890849 | 0.79 | F10 (0.63) | F10PLGPLATKLK1PRSS1 | |
| SCHEMBL890606 | 0.79 | F10 (0.63) | F10PLGPLATKLK1PRSS1 | |
| SCHEMBL1341922 | 0.78 | F10 (0.49) | F10PLAU | |
| SCHEMBL14404546 | 0.76 | NR1H4 (0.44) | F10 | |
| SCHEMBL14404265 | 0.75 | L3MBTL1 (0.54) | — | |
| SCHEMBL891006 | 0.74 | F10 (1.00) | F10PLGPLATKLK1PRSS1 | |
| SCHEMBL12133187 | 0.73 | F10 (0.85) | F10PLGPLATKLK1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | F10 13/4885PLG 18/4885PLAT 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.